For Prescribing guidance for drugs in dementia on the SY MO website click here
Mild to moderately severe dementia in Alzheimer's disease.
See above for Prescribing guidance for drugs in dementia on SY MO website.
Rationale: 1,2b
Prescribing restricted to Specialist Clinics only.
Secondary care clinical specialists from memory services (and other older adult services / specialties) will assess, diagnose, start treatment and titrate to optimum dose before requesting primary care prescribing. Secondary and primary care clinicians should liaise proactively with each other for subsequent clinical follow ups, prescribing, guidance and queries.
GPwER (and other primary care healthcare professionals) can start the medication if they have specialist expertise in diagnosing and treating dementia.
Orodispersible tablets available for patients with swallowing difficulty.
NICE NG97 Dementia: assessment, management and support for people living with dementia and their carers.
NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease.
| Pack | Price |
|---|---|
| 28 tablet | £0.87 |
| Pack | Price |
|---|---|
| 28 tablet | £1.15 |
Mild to moderately severe dementia in Alzheimer's disease.
See above for Prescribing guidance for drugs in dementia on SY MO website.
Rationale: 1,2b
Prescribing restricted to specialist clinics only.
Secondary care clinical specialists from memory services (and other older adult services / specialties) will assess, diagnose, start treatment and titrate to optimum dose before requesting primary care prescribing. Secondary and primary care clinicians should liaise proactively with each other for subsequent clinical follow ups, prescribing, guidance and queries.
GPwER (and other primary care healthcare professionals) can start the medication if they have specialist expertise in diagnosing and treating dementia.
NICE NG97 Dementia: assessment, management and support for people living with dementia and their carers
NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
| Pack | Price |
|---|---|
| 56 tablet |
| Pack | Price |
|---|---|
| 28 capsule | £51.88 |
| Pack | Price |
|---|---|
| 56 tablet |
| Pack | Price |
|---|---|
| 28 capsule | £64.90 |
| Pack | Price |
|---|---|
| 28 capsule | £79.80 |
Moderate to severe dementia in Alzheimer's disease.
See above for Prescribing guidance for drugs in dementia on SY MO website.
Rationale: 1,2b
Prescribing restricted to Specialist Clinics only.
Secondary care clinical specialists from memory services (and other older adult services / specialties) will assess, diagnose, start treatment and titrate to optimum dose before requesting primary care prescribing. Secondary and primary care clinicians should liaise proactively with each other for subsequent clinical follow ups, prescribing, guidance and queries.
GPwER (and other primary care healthcare professionals) can start the medication if they have specialist expertise in diagnosing and treating dementia.
For cost-effective prescribing it is recommended that oral solution is prescribed where clinically appropriate - Memantine orodispersible tablets are Grey listed
NICE NG97 Dementia: assessment, management and support for people living with dementia and their carers
NICE TA217 Memantine for the treatment of Alzheimer's disease
Advice for healthcare professionals:
* There are differences in dose delivery between the pump device and dropper device for memantine
* Please be vigilant regarding dose delivery for memantine products, particularly during the transition period from the dropper device to the new pump device. We request that you also advise patients and their caregivers:
- how to use the new pump device to deliver the prescribed dose
- to carefully read the Patient Information Leaflet for memantine oral solution
delivered by a pump device
| Pack | Price |
|---|---|
| 112 tablet | |
| 28 tablet | £1.04 |
| 56 tablet | |
| 7 tablet |
| Pack | Price |
|---|---|
| 28 tablet | £1.39 |
| 7 tablet |
Mild to moderately severe dementia in Alzheimer's disease.
See above for Prescribing guidance for drugs in dementia on SY MO website.
Rationale: 1,2b
Prescribing restricted to specialist clinics only.
Secondary care clinical specialists from memory services (and other older adult services / specialties) will assess, diagnose, start treatment and titrate to optimum dose before requesting primary care prescribing. Secondary and primary care clinicians should liaise proactively with each other for subsequent clinical follow ups, prescribing, guidance and queries.
GPwER (and other primary care healthcare professionals) can start the medication if they have specialist expertise in diagnosing and treating dementia.
Rivastigmine may be prescribed for Parkinson’s related dementia and will come under the Parkinson’s Shared care protocol.
NICE NG97 Dementia: assessment, management and support for people living with dementia and their carers
NICE TA217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
Transdermal patch - Prescribe by Brand name
Refer to BNF and each SPC for dose equivalence and conversion when switching oral to transdermal
| Pack | Price |
|---|---|
| 28 capsule | £1.64 |
| 56 capsule |
| Pack | Price |
|---|---|
| 28 capsule | £1.81 |
| 56 capsule |
| Pack | Price |
|---|---|
| 28 capsule | £2.98 |
| 56 capsule |
| Pack | Price |
|---|---|
| 28 capsule | £4.13 |
| 56 capsule |
Antipsychotic use in dementia
Rationale 1,2
NICE NG97 Dementia: assessment, management and support for people living with dementia and their carers
MHRA Drug Safety Update November 2013
Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery.
Treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease in adults that are apolipoprotein E ε4 heterozygotes or non-carriers
rationale 5
NICE TA in development
For the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein Eε4 (ApoEε4) heterozygotes or non-carriers
Rationale 6
NICE TA in development
Moderate to severe dementia in Alzheimer's disease & Oscillopsia in multiple sclerosis
For cost-effective prescribing it is recommended that oral solution is prescribed where clinically appropriate
Rationale 4
| Pack | Price |
|---|---|
| 28 tablet | £24.99 |
| Pack | Price |
|---|---|
| 28 tablet | £49.98 |